藥用明膠市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、原料、功能、最終用途、地區和競爭格局分類，2021-2031年

全球藥用明膠市場預計將從 2025 年的 21.2 億美元成長到 2031 年的 30.3 億美元，複合年成長率為 6.13%。

這種源自膠原蛋白部分水解的高分子量生物聚合物在硬膠囊和軟膠囊的生產、用作血漿擴容劑以及穩定疫苗製劑方面發揮著至關重要的作用。其成長主要受全球慢性病盛行率上升和老年人口不斷成長的推動，這兩方面都要求開發有效的口服給藥系統以提高患者的依從性和生物利用度。該材料優異的功能特性，例如良好的成膜性和生物相容性，進一步鞏固了其在臨床應用中的重要地位。然而，原料成本固有的波動性在一定程度上限制了其成長。尤其值得一提的是，到2025年，健康和營養領域已被確定為主要應用領域，54%的受訪行業專業人士在該領域工作，這凸顯了製藥和膳食補充劑行業對這種多功能添加劑的高度依賴。

市場促進因素

推動藥用明膠市場發展的主要因素是軟膠囊和硬膠囊製劑需求的不斷成長。這些製劑能夠有效掩蓋藥物味道並改善吞嚥性，從而顯著提高患者的用藥依從性。明膠在這些劑型中至關重要，它提供了活性成分（API）可靠封裝所需的關鍵機械強度和溶解性。這項強勁的需求體現在Nitta Gelatin India Limited截至2025年10月的會計年度財務業績中，該公司銷售額成長至14.193億印度盧比，主要來自其藥用輔料業務。同時，受消費者對預防性醫療保健解決方案日益成長的興趣推動，營養保健品和膳食補充劑行業的快速擴張也進一步促進了市場成長。製造商擴大將藥用明膠應用於強化機能性食品和軟糖類補充劑，因為這些產品對質地和穩定性要求較高。這一趨勢得到了膳食補充劑使用量增加的支持。根據負責任營養委員會 (CRN) 2024 年 10 月的報告顯示，服用鎂補充劑的膳食補充劑使用者比例上升至 23%。像新田明膠株式會社這樣的主要生產商，在截至 2025 年 9 月的六個月內實現了 184.99 億日元的銷售額，保持著強勁的銷售勢頭，這表明明膠在臨床和健康領域都發揮著至關重要的作用。

市場挑戰

原料成本的顯著波動對全球藥用明膠市場構成重大挑戰。這主要是由於該市場對畜牧產品的高度依賴。藥用明膠是肉類加工業的衍生性商品，容易受到多種外部因素的影響，包括衛生法規、牲畜疾病爆發以及牲畜數量波動。這種依賴導致供應鏈脆弱，常常引發價格飆升，並給製藥企業帶來巨大的採購風險，使關鍵藥物遞送系統的成本管理更加複雜，並阻礙了對明膠製劑的長期投資。原料供應的不穩定性直接限制了滿足不斷成長的需求所需的藥用級添加劑的供應，從而阻礙了市場的擴充性。而關鍵地區牲畜數量的下降進一步加劇了這個問題。例如，根據歐洲明膠製造商協會（GME）的數據，預計到 2024 年，歐洲豬產量將下降至約 2.18 億頭。這些供應限制迫使製造商在高成本條件下運營，導致儘管明膠具有固有的功能優勢，但藥用級明膠在大眾市場的普及速度卻有所放緩。

市場趨勢

隨著市場向再生醫學和止血應用領域的拓展，藥用明膠正經歷重大變革，並逐漸確立其作為先進臨床設備基礎生物材料的地位。製造商正積極地重新設計明膠的理化性質，超越傳統的封裝應用，開發出諸如液體止血劑、創傷治療支架和模擬細胞外基質的生物墨水等創新解決方案。主要產業參與者為實現投資組合多元化而投入巨資，這為向高價值生物醫學解決方案的策略轉型提供了支持。達令原料公司（Darling Ingredients）的全球原料業務就是一個典型的例子，該業務預計在2025年第三季實現2.48億美元的息稅折舊攤銷前利潤（EBITDA），從而能夠投資於下一代醫療設備。此外，由於全球對符合嚴格的清真、猶太潔食和魚素飲食要求的非哺乳動物來源輔料的需求不斷成長，海洋來源藥用明膠的商業化進程也在加速。這一趨勢促使生產商將其原料供應鏈從牛和豬皮轉向冷水魚皮，後者在提供類似功能性能的同時，避免了與動物疾病相關的監管障礙。 Nitta Gelatin India Limited 在其 2024-25 年度報告中公佈的稅前淨利為 10.968 億盧比，凸顯了調整生產組合以適應這些不斷變化的民族和宗教市場需求的商業性盈利和盈利能力。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球藥用明膠市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 按類型（A 型、B 型）
  • 依原料（豬肉、牛、牛、魚、家禽）分類
  • 依功能分類（穩定、增稠、凝膠等）
  • 最終用途類別（硬膠囊、軟膠囊、錠劑、可吸收止血劑、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美藥用明膠市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲藥用明膠市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區藥用明膠市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲藥用明膠市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲藥用明膠市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章 全球藥用明膠市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Gelita AG
• Trobas Pharmaceutical gelatine BV
• Rousselot SAS
• Gelatines Weishardt SAS
• Sterling Biotec Ltd.
• Catalent, Inc
• Nitta Pharmaceutical Gelatin India Limited
• Aspire Pharmaceuticals
• Gelco International
• Lapi Gelatine Spa

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Pharmaceutical Gelatin Market is projected to expand from USD 2.12 Billion in 2025 to USD 3.03 Billion by 2031, demonstrating a Compound Annual Growth Rate (CAGR) of 6.13%. This high-molecular-weight biopolymer, derived from the partial hydrolysis of collagen, is crucial for manufacturing hard and soft capsules, serving as a plasma expander, and stabilizing vaccine formulations. Its growth is primarily fueled by the increasing worldwide incidence of chronic diseases and an expanding elderly population, both of which necessitate effective oral drug delivery systems to boost patient compliance and bioavailability. The material's exceptional functional attributes, such as superior film-forming capabilities and biocompatibility, further solidify its indispensable role in clinical applications. However, this growth is somewhat constrained by the inherent volatility of raw material costs. Notably, in 2025, the health and nutrition sector was identified as the predominant application area, with 54% of surveyed industry professionals operating within this segment, highlighting the critical reliance of both pharmaceutical and nutraceutical industries on this versatile excipient.

Market Driver

A key driver for the pharmaceutical gelatin market is the escalating demand for softgel and hard capsule delivery systems, which significantly enhance patient compliance by effectively masking taste and facilitating ease of swallowing. Gelatin is fundamental to these dosage forms, providing essential mechanical strength and dissolution properties crucial for securely encapsulating active pharmaceutical ingredients (APIs). This robust demand is reflected in financial reports, such as Nitta Gelatin India Limited's October 2025 statement, which cited a revenue increase to 141.93 crore INR, largely attributable to its pharmaceutical excipient lines. Concurrently, the rapid expansion of the nutraceutical and dietary supplement industry further propels market growth, driven by consumers' growing preference for preventative health solutions. Manufacturers are increasingly adopting pharmaceutical-grade gelatin for fortified functional foods and gummy supplements, which require precise textural and stability characteristics. This trend is underscored by rising supplement usage, like magnesium's increase to 23% among all supplement users, as reported by the Council for Responsible Nutrition in October 2024. Major producers, such as Nitta Gelatin Inc. with net sales of 18,499 million JPY for the six months ending September 2025, are sustaining substantial turnover, indicating gelatin's vital role across both clinical and wellness sectors.

Market Challenge

The significant volatility in raw material costs represents a critical challenge for the global pharmaceutical gelatin market, largely due to its heavy reliance on livestock by-products. As a derivative of the meat processing industry, pharmaceutical gelatin is susceptible to various external pressures, including sanitary regulations, animal disease outbreaks, and fluctuations in livestock populations. This dependency creates a fragile supply chain, often leading to sudden price escalations and significant procurement risks for pharmaceutical manufacturers, complicating cost management for essential drug delivery systems and deterring long-term investments in gelatin-based formulations. This instability in raw material supply directly impedes market scalability by limiting the availability of pharmaceutical-grade excipients needed to meet increasing demand. The issue is compounded by a contraction in livestock numbers in key regions, such as the estimated decline in European porcine production to approximately 218 million heads in 2024, according to Gelatine Manufacturers of Europe (GME). Such supply constraints force manufacturers to operate in a high-cost environment, thereby slowing the broader adoption of gelatin in mass-market pharmaceutical applications, despite its inherent functional advantages.

Market Trends

The market is undergoing a significant transformation with the expansion into regenerative medicine and hemostatic applications, positioning pharmaceutical gelatin as a cornerstone biomaterial for advanced clinical devices. Manufacturers are actively re-engineering gelatin's physicochemical properties to develop innovative solutions like flowable hemostats, wound healing scaffolds, and bio-inks that mimic the extracellular matrix, moving beyond its traditional role in encapsulation. This strategic shift towards high-value biomedical solutions is supported by substantial capital allocation from leading industry players who are diversifying their portfolios, exemplified by Darling Ingredients' global ingredients business achieving an EBITDA of $248 million in Q3 2025, enabling investments in next-generation medical devices. Additionally, the increasing commercialization of marine-sourced pharmaceutical gelatin is accelerating in response to a growing global demand for non-mammalian excipients, which align with strict Halal, Kosher, and pescatarian dietary requirements. This trend prompts producers to diversify their raw material supply chains beyond bovine and porcine sources to include cold-water fish skins, which offer comparable functional performance while circumventing regulatory hurdles associated with animal diseases. The commercial viability and profitability of adapting production portfolios to these evolving ethno-religious market needs are highlighted by Nitta Gelatin India Limited's reported profit before tax of 109.68 crore INR in its Annual Report 2024-25.

Key Market Players

• Gelita AG
• Trobas Pharmaceutical gelatine B.V
• Rousselot SAS
• Gelatines Weishardt SAS
• Sterling Biotec Ltd.
• Catalent, Inc
• Nitta Pharmaceutical Gelatin India Limited
• Aspire Pharmaceuticals
• Gelco International
• Lapi Gelatine S.p.a

Report Scope

In this report, the Global Pharmaceutical Gelatin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pharmaceutical Gelatin Market, By Type

• Type A
• Type B

Pharmaceutical Gelatin Market, By Source

• Porcine
• Bovine Skin
• Bovine Bone
• Fish
• Poultry

Pharmaceutical Gelatin Market, By Function

• Stabilizing
• Thickening
• Gelling
• Others

Pharmaceutical Gelatin Market, By End User

• Hard Capsule
• Soft Capsule
• Tablet
• Absorbable Hemostat
• Others

Pharmaceutical Gelatin Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharmaceutical Gelatin Market.

Available Customizations:

Global Pharmaceutical Gelatin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pharmaceutical Gelatin Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Type A, Type B)
  • 5.2.2. By Source (Porcine, Bovine Skin, Bovine Bone, Fish, Poultry)
  • 5.2.3. By Function (Stabilizing, Thickening, Gelling, Others)
  • 5.2.4. By End User (Hard Capsule, Soft Capsule, Tablet, Absorbable Hemostat, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Pharmaceutical Gelatin Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Source
  • 6.2.3. By Function
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pharmaceutical Gelatin Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Source
      • 6.3.1.2.3. By Function
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Pharmaceutical Gelatin Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Source
      • 6.3.2.2.3. By Function
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Pharmaceutical Gelatin Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Source
      • 6.3.3.2.3. By Function
      • 6.3.3.2.4. By End User

7. Europe Pharmaceutical Gelatin Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Source
  • 7.2.3. By Function
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pharmaceutical Gelatin Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Source
      • 7.3.1.2.3. By Function
      • 7.3.1.2.4. By End User
  • 7.3.2. France Pharmaceutical Gelatin Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Source
      • 7.3.2.2.3. By Function
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Pharmaceutical Gelatin Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Source
      • 7.3.3.2.3. By Function
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Pharmaceutical Gelatin Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Source
      • 7.3.4.2.3. By Function
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Pharmaceutical Gelatin Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Source
      • 7.3.5.2.3. By Function
      • 7.3.5.2.4. By End User

8. Asia Pacific Pharmaceutical Gelatin Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Source
  • 8.2.3. By Function
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Pharmaceutical Gelatin Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Source
      • 8.3.1.2.3. By Function
      • 8.3.1.2.4. By End User
  • 8.3.2. India Pharmaceutical Gelatin Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Source
      • 8.3.2.2.3. By Function
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Pharmaceutical Gelatin Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Source
      • 8.3.3.2.3. By Function
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Pharmaceutical Gelatin Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Source
      • 8.3.4.2.3. By Function
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Pharmaceutical Gelatin Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Source
      • 8.3.5.2.3. By Function
      • 8.3.5.2.4. By End User

9. Middle East & Africa Pharmaceutical Gelatin Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Source
  • 9.2.3. By Function
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Pharmaceutical Gelatin Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Source
      • 9.3.1.2.3. By Function
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Pharmaceutical Gelatin Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Source
      • 9.3.2.2.3. By Function
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Pharmaceutical Gelatin Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Source
      • 9.3.3.2.3. By Function
      • 9.3.3.2.4. By End User

10. South America Pharmaceutical Gelatin Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Source
  • 10.2.3. By Function
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Pharmaceutical Gelatin Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Source
      • 10.3.1.2.3. By Function
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Pharmaceutical Gelatin Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Source
      • 10.3.2.2.3. By Function
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Pharmaceutical Gelatin Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Source
      • 10.3.3.2.3. By Function
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Pharmaceutical Gelatin Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Gelita AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Trobas Pharmaceutical gelatine B.V
• 15.3. Rousselot SAS
• 15.4. Gelatines Weishardt SAS
• 15.5. Sterling Biotec Ltd.
• 15.6. Catalent, Inc
• 15.7. Nitta Pharmaceutical Gelatin India Limited
• 15.8. Aspire Pharmaceuticals
• 15.9. Gelco International
• 15.10. Lapi Gelatine S.p.a

16. Strategic Recommendations

17. About Us & Disclaimer